U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C62H86N12O16
Molecular Weight 1255.417
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DACTINOMYCIN

SMILES

[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C3=C4N=C5C(OC4=C(C)C=C3)=C(C)C(=O)C(N)=C5C(=O)N[C@H]6[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]7([H])CCCN7C(=O)[C@H](NC6=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C

InChI

InChIKey=RJURFGZVJUQBHK-IIXSONLDSA-N
InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1

HIDE SMILES / InChI

Molecular Formula C62H86N12O16
Molecular Weight 1255.417
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1734954

Dactinomycin (actinomycin D) was isolated from Streptomyces by Selman Waksman in 1940s. The antibiotic shows anti-cancer activity; it was approved by FDA for the treatment of different cancer conditions among which are Ewing's sarcoma, Wilm's tumor, gestational trophoblastic disease, etc. Dactinomycin exerts its action by binding to DNA (preferably to GC motif) and thus inhibiting transcription.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
156.25 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Palliative
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Palliative
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Palliative
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
30.3 μg/mL
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
25.1 ng/mL
1.1 mg/m² unknown, intravenous
dose: 1.1 mg/m²
route of administration: Intravenous
experiment type: UNKNOWN
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
142.4 mg × h/L
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.67 μg × min/L
1.1 mg/m² unknown, intravenous
dose: 1.1 mg/m²
route of administration: Intravenous
experiment type: UNKNOWN
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.8 h
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
28.5 h
1.1 mg/m² unknown, intravenous
dose: 1.1 mg/m²
route of administration: Intravenous
experiment type: UNKNOWN
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Other AEs: Pancytopenia, Mucositis...
Other AEs:
Pancytopenia (1 patient)
Mucositis (severe, 1 patient)
Pancreatitis (1 patient)
Hyponatremia (1 patient)
Hypocalcemia (1 patient)
Respiratory distress (1 patient)
Melena (1 patient)
Sources:
0.15 ug/kg multiple, intravenous (total)
Highest studied dose
Dose: 0.15 ug/kg
Route: intravenous
Route: multiple
Dose: 0.15 ug/kg
Sources:
unhealthy, 40-77 years
n = 2
Health Status: unhealthy
Condition: malignant melanoma
Age Group: 40-77 years
Sex: F
Population Size: 2
Sources:
1.5 mg/m2 single, intravenous
Highest studied dose
Dose: 1.5 mg/m2
Route: intravenous
Route: single
Dose: 1.5 mg/m2
Sources:
unknown, children
n = 1
Health Status: unknown
Age Group: children
Population Size: 1
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypocalcemia 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Hyponatremia 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Melena 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Pancreatitis 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Pancytopenia 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Respiratory distress 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Mucositis severe, 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids.
1999 Apr
Rapid nucleolytic degradation of the small cytoplasmic Y RNAs during apoptosis.
1999 Aug 27
VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism.
2000 Apr
Testin induction: the role of cyclic 3',5'-adenosine monophosphate/protein kinase A signaling in the regulation of basal and lonidamine-induced testin expression by rat sertoli cells.
2000 Dec
Carcinogenic nickel induces genes involved with hypoxic stress.
2000 Jan 1
Experimental model of hepatic venoocclusive disease (VOD) caused by dactinomycin--preliminary report about hepatoprotective effect of amifostine.
2000 May-Jun
Amphetamine induces differential changes in the gene expression of metabotropic glutamate receptor 5 in cultured cortical and hippocampal neurons.
2001 Aug
The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts.
2001 Feb
Cadmium-induced cell transformation and tumorigenesis are associated with transcriptional activation of c-fos, c-jun, and c-myc proto-oncogenes: role of cellular calcium and reactive oxygen species.
2001 Jun
Differential induction of rat hepatic cytochromes P450 3A1, 3A2, 2B1, 2B2, and 2E1 in response to pyridine treatment.
2001 Mar
Dual phases of functional change in norepinephrine transporter in cultured bovine adrenal medullary cells by long-term treatment with clozapine.
2001 May
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
2002 Dec 1
Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole.
2002 Jan
Reactive oxygen species alter gene expression in podocytes: induction of granulocyte macrophage-colony-stimulating factor.
2002 Jan
Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity.
2002 Jan 1
Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation.
2003 Mar 15
Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells.
2003 May 15
The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.
2003 Oct
Morphine suppresses lymphocyte apoptosis by blocking p53-mediated death signaling.
2003 Sep 5
Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes.
2004 Dec
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
2004 Dec 1
DEP-induced fra-1 expression correlates with a distinct activation of AP-1-dependent gene transcription in the lung.
2004 Feb
Endosulfan-mediated biochemical changes in the freshwater fish Clarias batrachus.
2004 Mar
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism.
2004 Nov
Coordinated secretion of alkaline phosphatase into serum and intestine in fat-fed rats.
2004 Sep-Oct
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells.
2005 Feb 10
Promoting insulin secretion in pancreatic islets by means of bisphenol A and nonylphenol via intracellular estrogen receptors.
2005 May
Patents

Sample Use Guides

Wilms’ Tumor, Childhood Rhabdomyosarcoma and Ewing’s Sarcoma: Regimens of 15 mcg/kg intravenously daily for five days administered in various combinations and schedules with other chemotherapeutic agents; Metastatic Nonseminomatous Testicular Cancer: 1000 mcg/m2 intravenously on Day 1 as part of a combination regimen with cyclophosphamide, bleomycin, vinblastine, and cisplatin; Gestational Trophoblastic Neoplasia: 12 mcg/kg intravenously daily for five days as a single agent. 500 mcg intravenously on Days 1 and 2 as part of a combination regimen with etoposide, methotrexate, folinic acid, vincristine, cyclophosphamide and cisplatin; Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies: 50 mcg (0.05 mg) per kilogram of body weight for lower extremity or pelvis, 35 mcg (0.035 mg) per kilogram of body weight for upper extremity.
Route of Administration: Intravenous
In Vitro Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/25932119
Human osteosarcoma cell line MG63 were incubated with dactinomycin (actinomycin D) at final concentrations of 0.1, 0.5, 1 and 5 uM during 0, 2, 6 and 24 hours. The drug was shown to inhibit the proliferation of cells by decreasing cyclin gene transcriptions.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:14:37 GMT 2023
Edited
by admin
on Sat Dec 16 16:14:37 GMT 2023
Record UNII
1CC1JFE158
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DACTINOMYCIN
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
DACTINOMYCIN [HSDB]
Common Name English
ACTINOMYCIN C1
Common Name English
ACTINOMYCIN D [WHO-IP]
Common Name English
DACTINOMYCIN [WHO-IP]
Common Name English
3H-PHENOXAZINE-1,9-DICARBOXAMIDE, 2-AMINO-N,N'-BIS(HEXADECAHYDRO-6,13-DIISOPROPYL-2,5,9-TRIMETHYL-1,4,7,11,14-PENTAOXO-1H-PYRROLO(2,1-I)(1,4,7,10,13)OXATETRAAZACYCLOHEXADECIN-10-YL)-4,6-DIMETHYL-3-OXO-
Common Name English
ACTINOMYCIN-D
Common Name English
ACTINOMYCIN I1
Common Name English
DILACTONE ACTINOMYCIN D ACID
Common Name English
ACTINOMYCIN D [JAN]
Common Name English
DACTINOMYCIN [USP-RS]
Common Name English
GNF-PF-2290
Code English
DACTINOMYCIN [USP MONOGRAPH]
Common Name English
ACTINOMYCIN D [IARC]
Common Name English
DACTINOMYCIN [MART.]
Common Name English
DACTINOMYCIN [USAN]
Common Name English
DACTINOMYCIN [VANDF]
Common Name English
MERACTINOMYCIN
Common Name English
Dactinomycin [WHO-DD]
Common Name English
ACTINOMYCIN X1
Common Name English
DACTINOMYCINUM [WHO-IP LATIN]
Common Name English
DACTINOMYCIN [MI]
Common Name English
DACTINOMYCIN [ORANGE BOOK]
Common Name English
N,N'-((2-AMINO-4,6-DIMETHYL-3-OXO-3H-PHENOXAZINE-1,9-DIYL)-BIS(CARBONYLIMINO(2-HYDROXYPROPYLIDENE)CARBONYLIMINOISOBUTYLIDENECARBONYL-1,2-PYRROLIDINEDIYLCARBONYL(METHYLIMINO)METHYLENECARBONYL))BIS(N-METHYL-L-VALINE) DILACTONE
Common Name English
NSC-3053
Code English
Actinomycin D
WHO-IP  
Common Name English
NCI-C04682
Code English
ACTINOMYCIN IV
Common Name English
dactinomycin [INN]
Common Name English
ONCOSTATIN K
Common Name English
COSMEGEN
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C204
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
NDF-RT N0000000233
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
LIVERTOX NBK548778
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
IARC Actinomycin D
NDF-RT N0000000150
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
NDF-RT N0000180850
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
WHO-ATC L01DA01
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
WHO-VATC QL01DA01
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1162400
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
HSDB
3220
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
PUBCHEM
457193
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
DRUG BANK
DB00970
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
MERCK INDEX
m4067
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY Merck Index
LACTMED
Dactinomycin
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
EVMPD
SUB129914
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
CAS
50-76-0
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
FDA UNII
1CC1JFE158
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
NCI_THESAURUS
C412
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-063-6
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
EPA CompTox
DTXSID9020031
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
DAILYMED
1CC1JFE158
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DACTINOMYCIN
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY Description: An orange-red to red, crystalline powder.Solubility: Soluble in water at 10 ?C and slightly soluble in water at 37 ?C; freely soluble in ethanol (~750 g/l) TS and methanol R;very slightly soluble in ether R.Category: Cytotoxic drug.Storage: Dactinomycin should be kept in a tightly closed container, protected from light, and stored at a temperature notexceeding 40 ?C.Additional information: Dactinomycin is hygroscopic and is affected by light and heat.CAUTION: Dactinomycin must be handled with care, avoiding contact with the skin and inhalation of airborne particles.
EVMPD
SUB13528MIG
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
CHEBI
27666
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
MESH
D003609
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
ChEMBL
CHEMBL1554
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
SMS_ID
100000085032
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
INN
1155
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
RXCUI
3100
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY RxNorm
WIKIPEDIA
Dactinomycin
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
DRUG CENTRAL
774
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
NSC
3053
Created by admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC